These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32218533)

  • 41. Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor--feasibility and efficacy of multimodal therapy in a long-term survivor.
    Seeringer A; Reinhard H; Hasselblatt M; Schneppenheim R; Siebert R; Bartelheim K; Leuschner I; Frühwald MC
    Cancer Genet; 2014 Sep; 207(9):429-33. PubMed ID: 25262118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013.
    Bourdeaut F; Chi SN; Frühwald MC
    Cancer Genet; 2014 Sep; 207(9):346-51. PubMed ID: 25468731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis.
    Hasselblatt M; Thomas C; Hovestadt V; Schrimpf D; Johann P; Bens S; Oyen F; Peetz-Dienhart S; Crede Y; Wefers A; Vogel H; Riemenschneider MJ; Antonelli M; Giangaspero F; Bernardo MC; Giannini C; Ud Din N; Perry A; Keyvani K; van Landeghem F; Sumerauer D; Hauser P; Capper D; Korshunov A; Jones DT; Pfister SM; Schneppenheim R; Siebert R; Frühwald MC; Kool M
    Acta Neuropathol; 2016 Jul; 132(1):149-51. PubMed ID: 27067307
    [No Abstract]   [Full Text] [Related]  

  • 44. Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification.
    Fujisawa H; Takabatake Y; Fukusato T; Tachibana O; Tsuchiya Y; Yamashita J
    J Neurooncol; 2003 Jul; 63(3):257-62. PubMed ID: 12892231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
    Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
    J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Congenital multifocal rhabdoid tumor: a case with peculiar biological behavior and different response to treatment according to location (central nervous system and kidney).
    Pio L; Milanaccio C; Mascelli S; Raso A; Nozza P; Sementa AR; Cama A; Buffa P; Avanzini S; Vannati M; Capra V; Lanino E; Rossi A; Morana G; Magnano GM; Severino M; Garrè ML
    Cancer Genet; 2014 Sep; 207(9):441-4. PubMed ID: 25442925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
    Liu NQ; Paassen I; Custers L; Zeller P; Teunissen H; Ayyildiz D; He J; Buhl JL; Hoving EW; van Oudenaarden A; de Wit E; Drost J
    Nat Commun; 2023 Dec; 14(1):7762. PubMed ID: 38040699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.
    Pinto EM; Hamideh D; Bahrami A; Orr BA; Lin T; Pounds S; Zambetti GP; Pappo AS; Gajjar A; Agnihotri S; Broniscer A
    Acta Neuropathol; 2018 Aug; 136(2):315-326. PubMed ID: 29428974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.
    Frühwald MC; Nemes K; Boztug H; Cornips MCA; Evans DG; Farah R; Glentis S; Jorgensen M; Katsibardi K; Hirsch S; Jahnukainen K; Kventsel I; Kerl K; Kratz CP; Pajtler KW; Kordes U; Ridola V; Stutz E; Bourdeaut F
    Fam Cancer; 2021 Oct; 20(4):305-316. PubMed ID: 33532948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.
    Kohashi K; Oda Y; Yamamoto H; Tamiya S; Izumi T; Ohta S; Taguchi T; Suita S; Tsuneyoshi M
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):817-24. PubMed ID: 17486366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Constitutional mosaicism of pathogenic variants in SMARCB1 in a subset of patients with sporadic rhabdoid tumors.
    Fleischmann LS; Nemes K; Glaser S; Kouroukli AG; Boros M; Bens S; Dahlum S; Kretzmer H; Oyen F; Gerss J; Hasselblatt M; Frühwald MC; Siebert R
    Neuro Oncol; 2024 Sep; ():. PubMed ID: 39288268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.
    Biegel JA; Zhou JY; Rorke LB; Stenstrom C; Wainwright LM; Fogelgren B
    Cancer Res; 1999 Jan; 59(1):74-9. PubMed ID: 9892189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS).
    Kordes U; Bartelheim K; Modena P; Massimino M; Biassoni V; Reinhard H; Hasselblatt M; Schneppenheim R; Frühwald MC
    Pediatr Blood Cancer; 2014 May; 61(5):919-21. PubMed ID: 24123847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
    Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R
    Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor.
    Boudjemaa S; Petit A; Dainese L; Bourdeaut F; Lipsett J; Coulomb A
    Pediatr Dev Pathol; 2015; 18(5):401-4. PubMed ID: 25751458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
    Uno K; Takita J; Yokomori K; Tanaka Y; Ohta S; Shimada H; Gilles FH; Sugita K; Abe S; Sako M; Hashizume K; Hayashi Y
    Genes Chromosomes Cancer; 2002 May; 34(1):33-41. PubMed ID: 11921280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
    Le Quang M; Ranchère-Vince D; Le Loarer F
    Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atypical Teratoid/Rhabdoid Sellar Tumor in an Adult with a Familial History of a Germline SMARCB1 Mutation: Case Report and Review of the Literature.
    Voisin MR; Ovenden C; Tsang DS; Gupta AA; Huang A; Gao AF; Diamandis P; Almeida JP; Gentili F
    World Neurosurg; 2019 Jul; 127():336-345. PubMed ID: 31004861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.
    Bahrami A; Lee S; Caradine KD; Raimondi SC; Folpe AL
    Cancer Genet; 2014 Sep; 207(9):437-40. PubMed ID: 25312828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.